• Home
  • Search Results
  • Cardiovascular autonomic dysfunction in a novel rodent model of polycystic kidney disease.

Cardiovascular autonomic dysfunction in a novel rodent model of polycystic kidney disease.

Autonomic neuroscience : basic & clinical (2009-10-15)
Joanne L Harrison, Cara M Hildreth, Stephen M Callahan, Ann K Goodchild, Jacqueline K Phillips

Autonomic dysfunction, hypertension and cardiovascular morbidity in end stage renal disease are critically linked, however there are limited models available to investigate this relationship and develop clinical interventions. This study aimed to define the relationship between hypertension and autonomic function in a new rodent model of polycystic kidney disease (PKD). Using measures of heart rate and systolic blood pressure variability (HRV, SBPV), and time domain analysis of cardiac and sympathetic baroreflex function, we compared the Lewis PKD model (LPK) to a Lewis control. Systolic BP and SBPV were significantly higher in LPK vs. Lewis (168+/-7 vs. 131+/-8mm Hg, P<or=0.01, total power: 11+/-3.1 vs. 1.3+/-0.3mm Hg/Hz(2), P<or=0.05). LPK has a higher resting HR (437+/-17 vs. 330+/-11 beats per minute [bpm], P<or=0.001) associated with reduced HRV (total power [1.7+/-0.3 vs. 4.6+/-1.1ms/Hz(2), P<or=0.01]). Atenolol decreased HR to a greater extent in the LPK (90+/-10 vs. 20+/-17bpm, P<or=0.001) while subsequent methylatropine administration produced a greater increase in Lewis HR (24+/-9 vs. 66+/-9bpm, P<or=0.01). No difference in intrinsic HR following both drugs existed. Cardiac baroreflex function was impaired in LPK vs. Lewis (0.6+/-0.4 vs. 1.2+/-0.2bpm/mm Hg P<or=0.05, and 0.3+/-0.1 vs. 3.1+/-0.6ms/mm Hg, P<or=0.001, respectively). The sympathetic baroreflex function curve was shifted upwards and towards the right in LPK (P<or=0.01). Sympathetic baroreflex gain was not altered. This data suggests that sympathetic hyperactivity and reduced vagal function underlies the hypertension and reduced cardiac baroreflex function in the LPK model.

Product Number
Product Description

Methylatropine bromide, European Pharmacopoeia (EP) Reference Standard

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.